Tim Kutzkey Purchases 11,893 Shares of Surrozen (NASDAQ:SRZN) Stock

Surrozen, Inc. (NASDAQ:SRZN) Director Tim Kutzkey acquired 11,893 shares of the firm’s stock in a transaction dated Thursday, January 15th. The stock was bought at an average price of $19.89 per share, with a total value of $236,551.77. Following the purchase, the director directly owned 1,005,732 shares in the company, valued at approximately $20,004,009.48. This trade represents a 1.20% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Tim Kutzkey also recently made the following trade(s):

• On Tuesday, January 20th, Tim Kutzkey bought 18,052 shares of Surrozen stock. The stock was acquired at an average cost of $19.60 per share, for a total transaction of $353,819.20.
• On Friday, January 16th, Tim Kutzkey purchased 2,562 shares of Surrozen stock. The shares were acquired at an average cost of $20.00 per share, with a total value of $51,240.00.
• On Wednesday, January 14th, Tim Kutzkey bought 5,523 shares of Surrozen stock. The shares were acquired at an average price of $19.99 per share, with a total value of $110,404.77.
• On Tuesday, January 13th, Tim Kutzkey acquired 12,470 shares of Surrozen stock. The shares were bought at an average cost of $19.80 per share, for a total transaction of $246,906.00.
• On Tuesday, January 6th, Tim Kutzkey purchased 15,100 shares of Surrozen stock. The shares were bought at an average price of $19.89 per share, for a total transaction of $300,339.00.
• On Friday, December 5th, Tim Kutzkey bought 30,884 shares of Surrozen stock. The shares were purchased at an average price of $19.54 per share, for a total transaction of $603,473.36.
• On Thursday, December 4th, Tim Kutzkey acquired 5,266 shares of Surrozen stock. The stock was purchased at an average price of $17.35 per share, with a total value of $91,365.10.
• On Thursday, November 13th, Tim Kutzkey purchased 315,457 shares of Surrozen stock. The stock was acquired at an average price of $12.65 per share, with a total value of $3,990,531.05.

Surrozen Price Performance

Shares of NASDAQ:SRZN opened at $19.17 on Thursday. Surrozen, Inc. has a 1-year low of $5.90 and a 1-year high of $24.94. The stock has a market cap of $164.29 million, a P/E ratio of -0.86 and a beta of 0.58. The firm has a fifty day moving average price of $19.11 and a 200 day moving average price of $14.17.

Surrozen (NASDAQ:SRZN) last announced its earnings results on Friday, November 7th. The company reported ($3.61) EPS for the quarter, missing analysts’ consensus estimates of ($1.17) by ($2.44). Surrozen had a negative net margin of 2,909.10% and a negative return on equity of 4,055.04%. The business had revenue of $0.98 million during the quarter. Sell-side analysts expect that Surrozen, Inc. will post -8.49 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have weighed in on SRZN shares. Wall Street Zen upgraded Surrozen to a “sell” rating in a research note on Friday, November 28th. Lifesci Capital upgraded Surrozen to a “strong-buy” rating in a research report on Thursday, November 13th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Surrozen in a research report on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Surrozen currently has an average rating of “Moderate Buy” and a consensus price target of $32.00.

Trending Headlines about Surrozen

Here are the key news stories impacting Surrozen this week:

• Positive Sentiment: Director Tim Kutzkey completed several open‑market buys on Jan 6, 13, 14, 15, 16 and 20 totaling tens of thousands of shares (~$641k reported across the most recent three purchases) and now directly owns ~1.02M shares — insider accumulation is often read as a bullish confidence vote. Surrozen (NASDAQ:SRZN) Director Purchases $51,240.00 in Stock
• Positive Sentiment: Major shareholder Group GP LP Column III mirrored the insider purchases (Jan 15, 16 and 20), increasing its stake by ~1.2–1.8% per disclosed tranche to ~1.02M shares — coordinated buying by a large holder reinforces the positive insider signal. Surrozen (NASDAQ:SRZN) Major Shareholder Group Gp Lp Column III Acquires 2,562 Shares
• Neutral Sentiment: The disclosures are routine SEC beneficial‑ownership filings that document the trades and updated holdings; they do not indicate corporate actions (e.g., buybacks or financings) by Surrozen itself. SEC filing — Kutzkey purchases
• Negative Sentiment: Company fundamentals remain weak: Surrozen reported a steep Q3 EPS miss (reported -$3.61 vs -$1.17 expected) and minimal revenue, leaving substantial operating losses that could cap the stock’s upside unless clinical or commercial progress materially improves. MarketBeat — SRZN profile

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of SRZN. Stempoint Capital LP boosted its position in shares of Surrozen by 185.1% in the second quarter. Stempoint Capital LP now owns 686,539 shares of the company’s stock worth $6,138,000 after acquiring an additional 445,713 shares during the last quarter. Stonepine Capital Management LLC increased its position in Surrozen by 7.1% during the second quarter. Stonepine Capital Management LLC now owns 306,029 shares of the company’s stock worth $2,736,000 after purchasing an additional 20,247 shares during the last quarter. Vanguard Group Inc. raised its stake in Surrozen by 21.7% during the third quarter. Vanguard Group Inc. now owns 266,418 shares of the company’s stock worth $3,433,000 after purchasing an additional 47,468 shares during the period. Acuta Capital Partners LLC boosted its holdings in shares of Surrozen by 5.0% in the 3rd quarter. Acuta Capital Partners LLC now owns 178,415 shares of the company’s stock valued at $2,299,000 after purchasing an additional 8,415 shares during the last quarter. Finally, Braidwell LP purchased a new stake in shares of Surrozen during the 2nd quarter valued at $1,252,000. Institutional investors and hedge funds own 66.57% of the company’s stock.

About Surrozen

Surrozen, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutic antibodies that target the Wnt signaling pathway for applications in tissue repair, regeneration and oncology. Founded in 2012 and headquartered in South San Francisco, California, the company leverages its proprietary SurroBody platform to design bispecific antibody molecules capable of modulating Wnt receptor activity with enhanced tissue specificity.

The SurroBody platform enables the generation of high-affinity, dual-binding antibodies engineered to either activate or inhibit Wnt signaling, a pathway critical to cell proliferation, differentiation and homeostasis.